These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16675710)

  • 1. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.
    Kralovics R; Teo SS; Li S; Theocharides A; Buser AS; Tichelli A; Skoda RC
    Blood; 2006 Aug; 108(4):1377-80. PubMed ID: 16675710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis.
    Colaizzo D; Amitrano L; Tiscia GL; Scenna G; Grandone E; Guardascione MA; Brancaccio V; Margaglione M
    J Thromb Haemost; 2007 Jan; 5(1):55-61. PubMed ID: 17059429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V6I7 F status, clonality, and antiphospholipid antibodies.
    Robertson B; Urquhart C; Ford I; Townend J; Watson HG; Vickers MA; Greaves M
    J Thromb Haemost; 2007 Aug; 5(8):1679-85. PubMed ID: 17596137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic mechanisms in myeloproliferative disorders.
    Delhommeau F; Pisani DF; James C; Casadevall N; Constantinescu S; Vainchenker W
    Cell Mol Life Sci; 2006 Dec; 63(24):2939-53. PubMed ID: 17131059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Life histories of myeloproliferative neoplasms inferred from phylogenies.
    Williams N; Lee J; Mitchell E; Moore L; Baxter EJ; Hewinson J; Dawson KJ; Menzies A; Godfrey AL; Green AR; Campbell PJ; Nangalia J
    Nature; 2022 Feb; 602(7895):162-168. PubMed ID: 35058638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clonal hematopoiesis mutation Jak2
    Molinaro R; Sellar RS; Vromman A; Sausen G; Folco E; Sukhova GK; McConke ME; Corbo C; Ebert BL; Libby P
    Int J Cardiol; 2024 Aug; 409():132184. PubMed ID: 38759798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping genotypes to chromatin accessibility profiles in single cells.
    Izzo F; Myers RM; Ganesan S; Mekerishvili L; Kottapalli S; Prieto T; Eton EO; Botella T; Dunbar AJ; Bowman RL; Sotelo J; Potenski C; Mimitou EP; Stahl M; El Ghaity-Beckley S; Arandela J; Raviram R; Choi DC; Hoffman R; Chaligné R; Abdel-Wahab O; Smibert P; Ghobrial IM; Scandura JM; Marcellino B; Levine RL; Landau DA
    Nature; 2024 May; 629(8014):1149-1157. PubMed ID: 38720070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Has Higher Proportion of Janus Kinase 2 V617F Mutation Compared to Paired EDTA-Whole Blood Sample: A Model for Somatic Mutation Quantification Using qPCR and the 2
    Barra GB; Santa Rita TH; Almeida ALSC; Jácomo RH; Nery LFA
    Diagnostics (Basel); 2020 Mar; 10(3):. PubMed ID: 32178286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular analysis of V617F mutation in Janus kinase 2 gene of breast cancer patients.
    Karim S; Malik IR; Nazeer Q; Zaheer A; Farooq M; Mahmood N; Malik A; Asif M; Mehmood A; Khan AR; Jabbar A; Arshad M; Yousafi Q; Hussain A; Mirza Z; Iqbal MA; Rasool M
    Saudi J Biol Sci; 2019 Sep; 26(6):1123-1128. PubMed ID: 31516339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk.
    Kishtagari A; Khan MAW; Li Y; Vlasschaert C; Marneni N; Silver AJ; von Beck K; Spaulding T; Stockton S; Snider C; Sochacki A; Dorand D; Mack TM; Ferrell PB; Xu Y; Bejan CA; Savona MR; Bick AG
    Blood Cancer J; 2024 Jan; 14(1):6. PubMed ID: 38225345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A New Murine Model of Clonal Hematopoiesis Investigates
    Patel AP; Natarajan P
    JACC Basic Transl Sci; 2019 Oct; 4(6):698-700. PubMed ID: 31713537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematopoietic JAK2
    Sano S; Walsh K
    J Cardiovasc Aging; 2021; 1():. PubMed ID: 34396370
    [No Abstract]   [Full Text] [Related]  

  • 13. A smoking gun? Clonal expansion in response to cigarette exposure.
    Nathan DI; Mascarenhas J
    Front Oncol; 2023; 13():1252643. PubMed ID: 37601662
    [No Abstract]   [Full Text] [Related]  

  • 14. Response to Letter to Editor "
    Sohrabi A
    J Cancer Prev; 2019 Mar; 24(1):61-62. PubMed ID: 30993098
    [No Abstract]   [Full Text] [Related]  

  • 15. Myeloproliferative Neoplasms: A Contemporary Review.
    Tefferi A; Pardanani A
    JAMA Oncol; 2015 Apr; 1(1):97-105. PubMed ID: 26182311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice.
    Tiedt R; Hao-Shen H; Sobas MA; Looser R; Dirnhofer S; Schwaller J; Skoda RC
    Blood; 2008 Apr; 111(8):3931-40. PubMed ID: 18160670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.
    Lundberg P; Karow A; Nienhold R; Looser R; Hao-Shen H; Nissen I; Girsberger S; Lehmann T; Passweg J; Stern M; Beisel C; Kralovics R; Skoda RC
    Blood; 2014 Apr; 123(14):2220-8. PubMed ID: 24478400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms.
    Schaub FX; Looser R; Li S; Hao-Shen H; Lehmann T; Tichelli A; Skoda RC
    Blood; 2010 Mar; 115(10):2003-7. PubMed ID: 20061559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival.
    Lasho TL; Jimma T; Finke CM; Patnaik M; Hanson CA; Ketterling RP; Pardanani A; Tefferi A
    Blood; 2012 Nov; 120(20):4168-71. PubMed ID: 22968464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms.
    Saint-Martin C; Leroy G; Delhommeau F; Panelatti G; Dupont S; James C; Plo I; Bordessoule D; Chomienne C; Delannoy A; Devidas A; Gardembas-Pain M; Isnard F; Plumelle Y; Bernard O; Vainchenker W; Najman A; Bellanné-Chantelot C;
    Blood; 2009 Aug; 114(8):1628-32. PubMed ID: 19564637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.